A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 Given With Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Biologic Therapy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 Given With Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Biologic Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms BALANCE-I
  • Sponsors AbbVie
  • Most Recent Events

    • 26 Oct 2017 Results (n=573) assessing population pharmacokinetics of Upadacitinib in healthy subjects and subjects with rheumatoid arthritis from NCT01741493, NCT02066389, and NCT01960855 studies, published in the Clinical Pharmacokinetics.
    • 17 Jun 2017 Results of pooled post-hoc analysis of two phase II studies including this study presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results of post hoc analysis from two trials (BALANCE-I and BALANCE-II) assessing onset of benefit with ABT-494 vs. placebo in rheumatoid arthritis patients presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top